Antibody combination therapy to suppress HIV-1
2022
Max Planck Institute for Dynamics and Self-Organization, Goettingen, Germany
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, the researchers propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which they parametrize using high-throughput HIV sequence data from bNAb-naive patients. The study shows that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. These results offer a rational therapy design for HIV and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
Armita Nourmohammad
Added on: 11-28-2022
[1] https://elifesciences.org/articles/76004[2] https://www.drugtargetreview.com/news/104186/how-to-select-the-best-combination-of-antibodies-to-treat-hiv/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Fusion+Antibodies+-+Antibodies+-+29.07.22&utm_term=How+to+select+the+best+combination+of+antibodies+to+treat+HIV&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=tCWdylyMr%2f90F%2fbBvRIVOYCNOufMxRhAaHPPx%2bQNVIHhUxjnBWNagb9HxuTqJlPO1VG%2blWPaPMQ95qTKCqJZDjx0STPo317UQLTn2RmYLv80gIMYNIom4hRXM3azsENmzz66lNQw%2f6%2ff3b%2b4KsVEoCmIblw4575RC%2buSotfg5Z%2blQ7vLqxZqxmCF2TUcVBofmntb3Y9X%2bem7z5PpHwrQoIE9edkzM1jNiZWTFYfHPXcGwurLuCvldwqxto5DIlX1JPdHCQVyHP1PBO%2bWrkasqg%3d%3d
